Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1989-5-18
|
| pubmed:abstractText |
Seven male, young subjects received twice daily 300 mg of pirazolac (PAA) for one week and twice daily 600 mg PAA for a further week as tablet. Plasma levels of PAA were monitored every day just before dosing and up to 72 hours after the last dose using a specific HPLC-method. During the first week of treatment trough steady state levels of Cssmin = 24 +/- 8 micrograms/ml were reached at day 4. After changing of dose regimen to twice daily 600 mg a new steady was established four days later with Cssmin = 62 +/- 15 micrograms/ml. PAA in the plasma was highly (99.2 +/- 0.8%) bound to plasma proteins. Time course of the decay of PAA levels in the plasma after the last dose was similar to that after a single administration.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0378-7966
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
215-20
|
| pubmed:dateRevised |
2011-2-2
|
| pubmed:meshHeading |
pubmed-meshheading:3240767-Administration, Oral,
pubmed-meshheading:3240767-Adult,
pubmed-meshheading:3240767-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:3240767-Blood Proteins,
pubmed-meshheading:3240767-Dose-Response Relationship, Drug,
pubmed-meshheading:3240767-Drug Administration Schedule,
pubmed-meshheading:3240767-Half-Life,
pubmed-meshheading:3240767-Humans,
pubmed-meshheading:3240767-Male,
pubmed-meshheading:3240767-Protein Binding,
pubmed-meshheading:3240767-Pyrazoles
|
| pubmed:articleTitle |
Pharmacokinetics of pirazolac, a new anti-inflammatory drug, in human volunteers. III. Steady state plasma levels.
|
| pubmed:affiliation |
Research Laboratories, Schering AG, Berlin, FRG.
|
| pubmed:publicationType |
Journal Article
|